DTIL – Precision BioSciences, Inc.
Precision BioSciences, Inc.DTIL
$4.01Name : Precision BioSciences, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $96,412,176.00
EPSttm : -8.96
Precision BioSciences, Inc.
$4.01
1.59%$0.065Float Short %
7.26
Margin Of Safety %
Put/Call OI Ratio
0.02
EPS Next Q Diff
1.02
EPS Last/This Y
-7.21
EPS This/Next Y
3.05
Price
4.06
Target Price
32.5
Analyst Recom
1
Performance Q
-32.95
Relative Volume
4.93
Beta
1.31
Ticker: DTIL
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-01-13 | DTIL | 4.11 | 0.13 | 0.00 | 883 |
| 2026-01-14 | DTIL | 4.13 | 0.13 | 0.00 | 883 |
| 2026-01-15 | DTIL | 3.88 | 0.13 | 0.05 | 891 |
| 2026-01-16 | DTIL | 4.06 | 0.13 | 0.67 | 893 |
| 2026-01-20 | DTIL | 4.15 | 0.06 | 0.00 | 712 |
| 2026-01-21 | DTIL | 3.98 | 0.06 | 0.00 | 722 |
| 2026-01-22 | DTIL | 4.26 | 0.02 | 0.00 | 1880 |
| 2026-01-23 | DTIL | 4.19 | 0.02 | 0.00 | 1883 |
| 2026-01-26 | DTIL | 4.03 | 0.02 | 1.67 | 1887 |
| 2026-01-27 | DTIL | 4.13 | 0.03 | 0.00 | 1903 |
| 2026-01-28 | DTIL | 3.94 | 0.03 | 0.00 | 1921 |
| 2026-01-29 | DTIL | 3.99 | 0.03 | 0.00 | 1921 |
| 2026-01-30 | DTIL | 3.96 | 0.03 | 11.00 | 1992 |
| 2026-02-02 | DTIL | 3.96 | 0.02 | 0.00 | 1985 |
| 2026-02-03 | DTIL | 3.88 | 0.02 | 0.00 | 1990 |
| 2026-02-04 | DTIL | 3.81 | 0.02 | 0.00 | 2000 |
| 2026-02-05 | DTIL | 3.57 | 0.02 | 0.00 | 2002 |
| 2026-02-06 | DTIL | 3.8 | 0.02 | 999.99 | 2003 |
| 2026-02-09 | DTIL | 3.78 | 0.02 | 999.99 | 2003 |
| 2026-02-10 | DTIL | 3.76 | 0.02 | 0.00 | 2002 |
| 2026-02-11 | DTIL | 4.04 | 0.02 | 0.00 | 2135 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-01-13 | DTIL | 4.10 | 69.9 | - | -6.16 |
| 2026-01-14 | DTIL | 4.11 | 69.9 | - | -6.16 |
| 2026-01-15 | DTIL | 3.89 | 69.9 | - | -6.16 |
| 2026-01-16 | DTIL | 4.06 | 69.9 | - | -6.16 |
| 2026-01-20 | DTIL | 4.15 | 69.9 | - | -6.16 |
| 2026-01-21 | DTIL | 4.00 | 69.9 | - | -6.16 |
| 2026-01-22 | DTIL | 4.26 | 69.9 | - | -6.16 |
| 2026-01-23 | DTIL | 4.19 | 69.9 | - | -6.16 |
| 2026-01-26 | DTIL | 4.02 | 69.9 | - | -6.16 |
| 2026-01-27 | DTIL | 4.13 | 69.9 | - | -6.16 |
| 2026-01-28 | DTIL | 3.94 | 69.9 | - | -6.16 |
| 2026-01-29 | DTIL | 3.97 | 69.9 | - | -6.16 |
| 2026-01-30 | DTIL | 3.95 | 69.9 | - | -6.16 |
| 2026-02-02 | DTIL | 3.96 | 69.9 | - | -6.16 |
| 2026-02-03 | DTIL | 3.87 | 69.9 | - | -6.16 |
| 2026-02-04 | DTIL | 3.81 | 69.9 | - | -6.16 |
| 2026-02-05 | DTIL | 3.57 | 69.9 | - | -6.16 |
| 2026-02-06 | DTIL | 3.81 | 69.9 | - | -6.16 |
| 2026-02-09 | DTIL | 3.80 | 69.9 | - | -6.16 |
| 2026-02-10 | DTIL | 3.76 | 69.9 | - | -6.16 |
| 2026-02-11 | DTIL | 4.06 | 69.9 | - | -6.16 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-01-13 | DTIL | 0.12 | 1.03 | 5.75 |
| 2026-01-14 | DTIL | 0.12 | 1.03 | 5.75 |
| 2026-01-15 | DTIL | 0.12 | 1.03 | 5.75 |
| 2026-01-16 | DTIL | 0.12 | 1.03 | 5.75 |
| 2026-01-20 | DTIL | 0.12 | 1.03 | 5.75 |
| 2026-01-21 | DTIL | 0.12 | 1.03 | 5.75 |
| 2026-01-22 | DTIL | 0.12 | 1.03 | 5.75 |
| 2026-01-23 | DTIL | -1.31 | 1.03 | 5.75 |
| 2026-01-26 | DTIL | -1.31 | 13.07 | 5.84 |
| 2026-01-27 | DTIL | -1.23 | 13.07 | 5.84 |
| 2026-01-28 | DTIL | -1.23 | 13.07 | 6.97 |
| 2026-01-29 | DTIL | -1.23 | 13.07 | 6.97 |
| 2026-01-30 | DTIL | -1.23 | 13.07 | 6.97 |
| 2026-02-02 | DTIL | -1.23 | 13.08 | 6.97 |
| 2026-02-03 | DTIL | -1.23 | 13.08 | 6.97 |
| 2026-02-04 | DTIL | -1.23 | 13.08 | 6.97 |
| 2026-02-05 | DTIL | -1.23 | 13.08 | 6.97 |
| 2026-02-06 | DTIL | -1.23 | 13.08 | 6.97 |
| 2026-02-09 | DTIL | -1.23 | 15.09 | 6.97 |
| 2026-02-10 | DTIL | -1.23 | 15.09 | 6.97 |
| 2026-02-11 | DTIL | -1.23 | 15.09 | 7.26 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.84
Avg. EPS Est. Current Quarter
-0.64
Avg. EPS Est. Next Quarter
-0.82
Insider Transactions
-1.23
Institutional Transactions
15.09
Beta
1.31
Average Sales Estimate Current Quarter
9
Average Sales Estimate Next Quarter
4
Fair Value
Quality Score
10
Growth Score
31
Sentiment Score
4
Actual DrawDown %
99.1
Max Drawdown 5-Year %
-99.2
Target Price
32.5
P/E
Forward P/E
PEG
P/S
139.96
P/B
2.96
P/Free Cash Flow
EPS
-8.4
Average EPS Est. Cur. Y
-6.16
EPS Next Y. (Est.)
-3.11
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-11977.36
Relative Volume
4.93
Return on Equity vs Sector %
-530.5
Return on Equity vs Industry %
-514.1
EPS 1 7Days Diff
0.3
EPS 1 30Days Diff
0.25
EBIT Estimation
Precision BioSciences, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 67
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-3243 for the treatment of m.3243 associated mitochondrial myopathy. In addition, the company develops PBGENE-NVS (insertion) for sickle cell and beta thalassemia diseases; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LIVER (insertion), a liver directed target; PBGENE-CNS (excision), a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with Novartis Pharma AG to discover and develop in vivo gene editing products; TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; and iECURE, Inc. to develop ARCUS-based gene-insertion therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
stock quote shares DTIL – Precision BioSciences, Inc. Stock Price stock today
news today DTIL – Precision BioSciences, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch DTIL – Precision BioSciences, Inc. yahoo finance google finance
stock history DTIL – Precision BioSciences, Inc. invest stock market
stock prices DTIL premarket after hours
ticker DTIL fair value insiders trading